X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 38.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 47,668 shares of the company’s stock after acquiring an additional 13,328 shares during the quarter. SG Americas Securities LLC’s holdings in X4 Pharmaceuticals were worth $40,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of XFOR. ProShare Advisors LLC bought a new position in X4 Pharmaceuticals during the 2nd quarter worth approximately $31,000. State of Wisconsin Investment Board acquired a new stake in X4 Pharmaceuticals in the second quarter worth approximately $46,000. Virtu Financial LLC bought a new position in X4 Pharmaceuticals during the first quarter valued at about $45,000. BNP Paribas Arbitrage SNC boosted its position in shares of X4 Pharmaceuticals by 458,857.1% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 32,127 shares of the company’s stock valued at $62,000 after purchasing an additional 32,120 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in X4 Pharmaceuticals in the second quarter worth approximately $68,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $43,716.64. Following the completion of the transaction, the chief executive officer now directly owns 765,068 shares in the company, valued at $673,259.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Adam S. Mostafa sold 52,500 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $46,200.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $43,716.64. Following the completion of the sale, the chief executive officer now directly owns 765,068 shares in the company, valued at approximately $673,259.84. The disclosure for this sale can be found here. Insiders sold 185,708 shares of company stock worth $170,428 over the last ninety days. Company insiders own 1.08% of the company’s stock.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $1.26 on Monday. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.34 and a quick ratio of 5.34. The firm has a market cap of $211.60 million, a P/E ratio of -2.10 and a beta of 0.49. The stock’s 50-day moving average is $1.11 and its two-hundred day moving average is $0.92. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.57 and a fifty-two week high of $2.58.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.05. Analysts predict that X4 Pharmaceuticals, Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of X4 Pharmaceuticals in a research note on Friday, March 22nd.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.